The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Invasive Candidiasis Treatment Drug Market Research Report 2024

Global Invasive Candidiasis Treatment Drug Market Research Report 2024

Publishing Date : Jun, 2023

License Type :
 

Report Code : 1738871

No of Pages : 89

Ask Your Query

Synopsis
Global Invasive Candidiasis Treatment Drug market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Invasive Candidiasis Treatment Drug market research.

Key companies engaged in the Invasive Candidiasis Treatment Drug industry include GlaxoSmithKline, Merck & Co., Inc, Pfizer Inc, Cidara Therapeutics, Inc, Astellas Pharma Inc, Gilead Sciences, Inc, Novo Nordisk A/S (Xellia Pharmaceuticals), Biosergen AB and Matinas BioPharma Holdings, Inc, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.

When refers to consumption region, % value of Invasive Candidiasis Treatment Drug were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Invasive Candidiasis Treatment Drug market and estimated to attract more attentions from industry insiders and investors.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Invasive Candidiasis Treatment Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  • GlaxoSmithKline
  • Merck & Co., Inc
  • Pfizer Inc
  • Cidara Therapeutics, Inc
  • Astellas Pharma Inc
  • Gilead Sciences, Inc
  • Novo Nordisk A/S (Xellia Pharmaceuticals)
  • Biosergen AB
  • Matinas BioPharma Holdings, Inc
  • Pulmocide Ltd
  • F2G Ltd

Segment by Type

  • Azoles Drug
  • Echinocandins Drug
  • Allylamines Drug
  • Polyenes Drug
  • Others

Segment by Application

  • Hospital
  • Clinic
  • Others

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia, Nordic Countries, Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea,Southeast Asia, India, Australia, Rest of Asia)
  • Latin America (Mexico, Brazil, Rest of Latin America)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)

The Invasive Candidiasis Treatment Drug report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Invasive Candidiasis Treatment Drug Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Azoles Drug
1.2.3 Echinocandins Drug
1.2.4 Allylamines Drug
1.2.5 Polyenes Drug
1.2.6 Others
1.3 Market by Application
1.3.1 Global Invasive Candidiasis Treatment Drug Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Invasive Candidiasis Treatment Drug Market Perspective (2018-2029)
2.2 Invasive Candidiasis Treatment Drug Growth Trends by Region
2.2.1 Global Invasive Candidiasis Treatment Drug Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Invasive Candidiasis Treatment Drug Historic Market Size by Region (2018-2023)
2.2.3 Invasive Candidiasis Treatment Drug Forecasted Market Size by Region (2024-2029)
2.3 Invasive Candidiasis Treatment Drug Market Dynamics
2.3.1 Invasive Candidiasis Treatment Drug Industry Trends
2.3.2 Invasive Candidiasis Treatment Drug Market Drivers
2.3.3 Invasive Candidiasis Treatment Drug Market Challenges
2.3.4 Invasive Candidiasis Treatment Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Invasive Candidiasis Treatment Drug Players by Revenue
3.1.1 Global Top Invasive Candidiasis Treatment Drug Players by Revenue (2018-2023)
3.1.2 Global Invasive Candidiasis Treatment Drug Revenue Market Share by Players (2018-2023)
3.2 Global Invasive Candidiasis Treatment Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Invasive Candidiasis Treatment Drug Revenue
3.4 Global Invasive Candidiasis Treatment Drug Market Concentration Ratio
3.4.1 Global Invasive Candidiasis Treatment Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Invasive Candidiasis Treatment Drug Revenue in 2022
3.5 Invasive Candidiasis Treatment Drug Key Players Head office and Area Served
3.6 Key Players Invasive Candidiasis Treatment Drug Product Solution and Service
3.7 Date of Enter into Invasive Candidiasis Treatment Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Invasive Candidiasis Treatment Drug Breakdown Data by Type
4.1 Global Invasive Candidiasis Treatment Drug Historic Market Size by Type (2018-2023)
4.2 Global Invasive Candidiasis Treatment Drug Forecasted Market Size by Type (2024-2029)
5 Invasive Candidiasis Treatment Drug Breakdown Data by Application
5.1 Global Invasive Candidiasis Treatment Drug Historic Market Size by Application (2018-2023)
5.2 Global Invasive Candidiasis Treatment Drug Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Invasive Candidiasis Treatment Drug Market Size (2018-2029)
6.2 North America Invasive Candidiasis Treatment Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Invasive Candidiasis Treatment Drug Market Size by Country (2018-2023)
6.4 North America Invasive Candidiasis Treatment Drug Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Invasive Candidiasis Treatment Drug Market Size (2018-2029)
7.2 Europe Invasive Candidiasis Treatment Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Invasive Candidiasis Treatment Drug Market Size by Country (2018-2023)
7.4 Europe Invasive Candidiasis Treatment Drug Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Invasive Candidiasis Treatment Drug Market Size (2018-2029)
8.2 Asia-Pacific Invasive Candidiasis Treatment Drug Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Invasive Candidiasis Treatment Drug Market Size by Region (2018-2023)
8.4 Asia-Pacific Invasive Candidiasis Treatment Drug Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Invasive Candidiasis Treatment Drug Market Size (2018-2029)
9.2 Latin America Invasive Candidiasis Treatment Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Invasive Candidiasis Treatment Drug Market Size by Country (2018-2023)
9.4 Latin America Invasive Candidiasis Treatment Drug Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Invasive Candidiasis Treatment Drug Market Size (2018-2029)
10.2 Middle East & Africa Invasive Candidiasis Treatment Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Invasive Candidiasis Treatment Drug Market Size by Country (2018-2023)
10.4 Middle East & Africa Invasive Candidiasis Treatment Drug Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Detail
11.1.2 GlaxoSmithKline Business Overview
11.1.3 GlaxoSmithKline Invasive Candidiasis Treatment Drug Introduction
11.1.4 GlaxoSmithKline Revenue in Invasive Candidiasis Treatment Drug Business (2018-2023)
11.1.5 GlaxoSmithKline Recent Development
11.2 Merck & Co., Inc
11.2.1 Merck & Co., Inc Company Detail
11.2.2 Merck & Co., Inc Business Overview
11.2.3 Merck & Co., Inc Invasive Candidiasis Treatment Drug Introduction
11.2.4 Merck & Co., Inc Revenue in Invasive Candidiasis Treatment Drug Business (2018-2023)
11.2.5 Merck & Co., Inc Recent Development
11.3 Pfizer Inc
11.3.1 Pfizer Inc Company Detail
11.3.2 Pfizer Inc Business Overview
11.3.3 Pfizer Inc Invasive Candidiasis Treatment Drug Introduction
11.3.4 Pfizer Inc Revenue in Invasive Candidiasis Treatment Drug Business (2018-2023)
11.3.5 Pfizer Inc Recent Development
11.4 Cidara Therapeutics, Inc
11.4.1 Cidara Therapeutics, Inc Company Detail
11.4.2 Cidara Therapeutics, Inc Business Overview
11.4.3 Cidara Therapeutics, Inc Invasive Candidiasis Treatment Drug Introduction
11.4.4 Cidara Therapeutics, Inc Revenue in Invasive Candidiasis Treatment Drug Business (2018-2023)
11.4.5 Cidara Therapeutics, Inc Recent Development
11.5 Astellas Pharma Inc
11.5.1 Astellas Pharma Inc Company Detail
11.5.2 Astellas Pharma Inc Business Overview
11.5.3 Astellas Pharma Inc Invasive Candidiasis Treatment Drug Introduction
11.5.4 Astellas Pharma Inc Revenue in Invasive Candidiasis Treatment Drug Business (2018-2023)
11.5.5 Astellas Pharma Inc Recent Development
11.6 Gilead Sciences, Inc
11.6.1 Gilead Sciences, Inc Company Detail
11.6.2 Gilead Sciences, Inc Business Overview
11.6.3 Gilead Sciences, Inc Invasive Candidiasis Treatment Drug Introduction
11.6.4 Gilead Sciences, Inc Revenue in Invasive Candidiasis Treatment Drug Business (2018-2023)
11.6.5 Gilead Sciences, Inc Recent Development
11.7 Novo Nordisk A/S (Xellia Pharmaceuticals)
11.7.1 Novo Nordisk A/S (Xellia Pharmaceuticals) Company Detail
11.7.2 Novo Nordisk A/S (Xellia Pharmaceuticals) Business Overview
11.7.3 Novo Nordisk A/S (Xellia Pharmaceuticals) Invasive Candidiasis Treatment Drug Introduction
11.7.4 Novo Nordisk A/S (Xellia Pharmaceuticals) Revenue in Invasive Candidiasis Treatment Drug Business (2018-2023)
11.7.5 Novo Nordisk A/S (Xellia Pharmaceuticals) Recent Development
11.8 Biosergen AB
11.8.1 Biosergen AB Company Detail
11.8.2 Biosergen AB Business Overview
11.8.3 Biosergen AB Invasive Candidiasis Treatment Drug Introduction
11.8.4 Biosergen AB Revenue in Invasive Candidiasis Treatment Drug Business (2018-2023)
11.8.5 Biosergen AB Recent Development
11.9 Matinas BioPharma Holdings, Inc
11.9.1 Matinas BioPharma Holdings, Inc Company Detail
11.9.2 Matinas BioPharma Holdings, Inc Business Overview
11.9.3 Matinas BioPharma Holdings, Inc Invasive Candidiasis Treatment Drug Introduction
11.9.4 Matinas BioPharma Holdings, Inc Revenue in Invasive Candidiasis Treatment Drug Business (2018-2023)
11.9.5 Matinas BioPharma Holdings, Inc Recent Development
11.10 Pulmocide Ltd
11.10.1 Pulmocide Ltd Company Detail
11.10.2 Pulmocide Ltd Business Overview
11.10.3 Pulmocide Ltd Invasive Candidiasis Treatment Drug Introduction
11.10.4 Pulmocide Ltd Revenue in Invasive Candidiasis Treatment Drug Business (2018-2023)
11.10.5 Pulmocide Ltd Recent Development
11.11 F2G Ltd
11.11.1 F2G Ltd Company Detail
11.11.2 F2G Ltd Business Overview
11.11.3 F2G Ltd Invasive Candidiasis Treatment Drug Introduction
11.11.4 F2G Ltd Revenue in Invasive Candidiasis Treatment Drug Business (2018-2023)
11.11.5 F2G Ltd Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock